We collected clinical register data on children in two provinces of Kenya and conducted bivariate and multivariate analyses to assess characteristics associated with death. Among 987 children with tuberculosis (TB), pulmonary disease was diagnosed in 689 (70%) children. Final outcomes were known for 830 children, 40 (5%) of whom died during TB treatment. HIV test results were available for 670 (68%) children; 371 (55%) of whom tested positive. Only 63 of 134 (47%) of children <1 year were tested for HIV. There were no data on CD4 or anti-retroviral use. The relative risk for death for HIV-infected children compared to HIV-uninfected children was 9.3 for children <1 year [95% confidence interval (CI) 1.2-69.2], 3.9 for children aged 1-4 (95% CI 0.9-17.7) and 0.9 for children aged 5-14 (95% CI 0.3-2.6). In Kenya, HIV infection in children with TB is common, and our data suggest that HIV is particularly deadly in TB patients <1 year, the group with the lowest rate of testing. Poor data recording and reporting limit our understanding of TB in this age group. Expansion of HIV testing may improve survival, and more complete data recording and reporting will enhance our understanding of pediatric TB.
Introduction
Historically, efforts to control tuberculosis (TB) have focused on identifying and treating patients most likely to transmit the infection; consequently the World Health Organization (WHO) requests ageand sex-specific data only for cases of sputum smear-positive TB. Young children with TB have a higher risk of severe disease and death [1] , but since they usually have smear-negative pulmonary or extra-pulmonary TB, detailed information on them is not routinely available for review and analysis.
HIV confers an increased risk of death among children with TB [2] [3] [4] [5] [6] , but because data are sparse and diagnosis is difficult, this association is not as well-characterized as it is in adults. Awareness of HIV status in patients with TB is vitally important, as interventions like cotrimoxazole preventive therapy (CPT) and anti-retroviral therapy (ART) have been shown to significantly reduce mortality in patients with TB who have HIV from >50% to <10% [7] [8] [9] [10] [11] [12] [13] [14] [15] . Recently, Kenya has made significant progress toward the ultimate goal of universal HIV testing among patients with TB, testing 83% of all patients with TB in 2008, up from just 20% in 2004 [16] , but there are no national level data on HIV testing or prevalence among children with TB in Kenya.
Childhood TB remains a significant, but largely uncharacterized, public health concern in Kenya. We aimed to document the procedures used to diagnose TB, document the reporting and epidemiology of pediatric TB, and determine the association between HIV infection and mortality in children with TB in children in the two provinces with the highest rates of both TB incidence and HIV prevalence in the country [16] .
Methods and Materials

Data collection
We collected epidemiologic and clinical data from district registers on all children <15 years of age who registered for TB treatment in a convenience sample of three of four districts in Nairobi province and in two of twelve districts in Nyanza province between October 2006 and September 2007. Data were collected in September and October 2008 to ensure that sufficient time had passed for treatment to be completed and outcomes recorded. We limited our data collection to variables that were >20% complete in the registers.
Definitions used for data analysis
We defined a case of pediatric TB as a TB patient <15 years of age who was registered for TB treatment. We used standard WHO definitions for TB registration and treatment outcome categories [17] . Sputum microscopy results were recorded as Acid Fast Bacteria (AFB) positive (any sputum sample positive for AFB) or negative at initial TB diagnosis. If this was left blank in the register, we considered it not done. There were no notations indicating gastric lavage in the registers. Site of TB disease was recorded as pulmonary if the patient was thought to have pulmonary involvement, even in those with evidence for concomitant extra-pulmonary involvement, or extra-pulmonary if there was no evidence of disease involving the lungs.
Data analysis
To describe the epidemiology of TB, we calculated frequencies for selected variables. To determine characteristics associated with death during TB treatment, we compared patients who died to patients who had either completed treatment or were cured. We excluded patients who defaulted or transferred care since the final outcome for these patients was not known. We analyzed risks for death associated with age, type of TB (pulmonary or extrapulmonary), HIV status and province. Additionally, we examined the association between CPT use and death among patients with HIV infection. ART data were generally not available and could not be included in analysis. Patients who had no HIV test result documented were categorized as HIV unknown and were maintained as a separate category for analyses.
For bivariate analysis of categorical variables, we compared proportions using 2 and, when appropriate, Fisher's exact test. For multivariate analysis, we performed a log-binomial regression analysis to obtain adjusted relative risks. We included in our original model all characteristics noted above. We developed our model using manual backward stepwise variable selection, retaining variables that met the significance level p < 0.05.
Results
There were 987 children <15 years of age who registered for TB treatment between October 2006 and September 2007 in the selected districts, 577 from Nairobi and 410 from Nyanza. CD4 count and ART use were rarely recorded and we were unable to include them in our analyses. Overall, 467 (47%) children were female. A total of 491 (50%) children were <5 years of age, including 134 (14% of the total) <1 year. Pulmonary TB was rarely confirmed by sputum microscopy, and there were no recorded sputum culture results. There were six cases that were described as having extra-pulmonary disease in the registers, but had documented sputum smears positive for AFB; we counted those as pulmonary TB cases. Two hundred fifty-seven children (26%) had results reported for smear microscopy and, of those, 83 (32%) were AFB positive. Outcomes were recorded for 936 children (95%), 830 of whom had known outcomes (Table 1) .
Of 670 (68%) children who were tested for HIV infection, 371 (55%) were infected. Of the 134 children <1 year of age, 47% were tested for HIV, which compares to 70% of children aged 1-4 years, 76% of children aged 5-9 years and 68% of children aged 10-14 years old (Table 2) . When compared to all children aged 1 year or older, children under 1 year were significantly less commonly tested for HIV (p < 0.001). The HIV prevalence among those tested was similar across all age groups (Table 2) .
Overall, 790 (84%) children were reported as cured or completed treatment. Among the 40 (4%) children who were reported to have died during the course of treatment, the risk of death varied by age: 10 (9%) of 107 children under 1 year of age died compared to 6 (3%) of 180 children aged 10-14 years [relative risk (RR) 2.8, 95% confidence interval (CI) 1.0-7.5] ( Table 3 ). In bivariate analysis of the 580 (61%) children with known HIV status and TB treatment outcome, death was significantly more common in children with HIV: of 323 children with HIV, 25 (8%) died compared with 9 (4%) of 257 children without HIV (RR 2.3, 95% CI 1.1-5.0) ( Table 3) .
Among the 323 children with HIV, CPT was not associated with a lower risk of death: 20 (7%) of the 270 children receiving CPT died compared to five (9%) of the 53 children not given CPT (RR 0.8, 95% CI 0.3-2.0).
In multivariate analysis controlling for age, HIV status, site of TB and province, only younger age and HIV infection were significantly associated with death. Since only children with HIV infection were eligible for CPT, and since CPT was not associated with outcome in that group, we did not include it in our multivariate model. We found that age group significantly modified the effect of HIV on outcome. Since no other variables were significant in multivariate analysis, we addressed this interaction by assessing the association between HIV and death, stratified by age group. There were no deaths among the children without HIV test results between the ages of 5 and 9 years, so we combined this age group with the 10 to14 age group for analysis. Of the (2) 11 (3) 21 (2) a Percentages were rounded to the nearest integer and totals may add to less or greater than 100%. (83) 111 (83) 103 (80) 62 (78) a Data on site of disease was missing for one patient. b Denominator is sputum sent (n ¼ 11 for age <1 years; n ¼ 59 for age 1-4 years; n ¼ 67 for age 5-9 years; n ¼ 104 for age 10-14 years). Denominator is number tested for HIV (n ¼ 63 for age <1 year; n ¼ 249 for age 1-4 years; n ¼ 210 for age 5-9 years; n ¼ 148 for age 10-14 years). d Denominator is number tested positive (n ¼ 30 for age <1 year; n ¼ 133 for age 1-4 years; n ¼ 129 for age 5-9 years; n ¼ 79 for age 10-14 years).
TABLE 2 Clinical characteristics by age group
children under one year of age who were HIV infected, 8 (32%) of 25 died compared to 1 (3%) of 29 children without HIV infection (RR 9.3, 95% CI 1.2-69.2). Of the children aged one to four who were infected with HIV, nine (7%) of 121 died compared to two (2%) out of 105 children without HIV infection (RR 3.9, 95% CI 0.9-17.7). For the children between 5 and 14 years of age, HIV infection was not significantly associated with death (RR 0.9, 95% CI 0.3-2.6) ( Table 4) . Discussion Our review of pediatric TB helps characterize the distribution of TB among children in Kenya and highlights risks associated with death. In our sample of pediatric TB patients, half were under the age of five and, unlike adult TB patients, the gender distribution was nearly even. The association between HIV and death was much stronger in younger children than in older children, but the youngest children were least likely to be tested for HIV.
Awareness of HIV infection in patients with TB is critically important, as HIV infection is a potentially treatable risk factor for death [18] . Previous research has demonstrated increased mortality among pediatric TB patients with HIV infection and has demonstrated important co-factors, such as malnutrition, degree of immune suppression and clinical stage at diagnosis that contribute to increased mortality in pediatric TB patients with HIV infection [2] [3] [4] [5] [6] 13] . Our data indicate that the association between HIV and mortality in TB patients is much higher for children under the age of one than it is for older children; unfortunately this was also the group least likely to be tested for HIV. It may be that the absence or unwillingness of a parent to consent for HIV testing, clinician discomfort or lack of knowledge about how to offer pediatric testing or a lack of PCR testing are important barriers.
We did not observe an association between HIV and mortality in older children, and the reasons for this are not entirely clear. The rate of HIV disease progression is highly variable among infected children [19] [20] [21] [22] [23] and it may be that those who survive beyond early childhood are those who are at lower risk for disease progression; conversely, it may be that older children with HIV infection were more often treated with ART than younger children. It is also possible that our sample size was not large enough to detect any smaller associations that may have been present in the older age group.
There were several limitations of this study. This was a retrospective study, and the only data available were from the TB registers. The districts themselves were selected for convenience; it is possible that the sample of patients was not representative of the entire population and our conclusions may not be generalizable to the whole country. Data on CD4 or ART use were rarely recorded, which limits our analysis of the effect of HIV on death in children with TB, and is a major shortcoming in the surveillance of this population. In addition, the accuracy of data from the registers was not verified. Finally, the lack of bacteriologic confirmation of TB disease, common in resource-limited settings, made it impossible to know which children actually had TB. This diagnostic uncertainty limits the degree to which our findings can be generalized to children with confirmed TB disease.
Increasing HIV testing of children under the age of one should be an urgent priority, and focused research is needed to better elucidate reasons for low rates of testing. Given the likelihood that most young children are infected with TB in their homes, intensifying TB case finding and treatment among all pregnant women and new mothers and screening of all household contacts of adults with TB would likely help prevent disease and yield a significant mortality benefit among infants, and these approaches should be studied for effect. There is a disturbing lack of data about pediatric TB; in order to characterize and fully understand the scope of the problem, and to monitor the effects of interventions, more complete data on children with TB disease need to be routinely collected and reported to the national and international levels. Specific and concerted efforts to improve data collection should be adopted by national TB programs.
